Does Alive Max3 Potency Oral Interact with other Medications?

Severe Interactions

These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.

  • WEAK CYP3A4 INHIBITORS/LEMBOREXANT (> 5 MG)
  • WEAK CYP3A4 INHIBITORS/LOMITAPIDE (>30 MG)
  • ANTICHOLINERGICS; ANTISPASMODICS/PRAMLINTIDE
  • Serious Interactions

    These medications may interact and cause very harmful effects. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.

  • P-GLYCOPROTEIN (P-GP) INHIBITORS/BILASTINE
  • P-GLYCOPROTEIN (P-GP) INHIBITORS/DOXORUBICIN
  • P-GLYCOPROTEIN (P-GP) INHIBITORS/RELUGOLIX
  • WEAK CYP3A4 INHIBITORS/LONAFARNIB
  • CYP3A4 INDUCERS/LUMATEPERONE
  • P-GLYCOPROTEIN (P-GP) INHIBITORS/ORAL LEFAMULIN
  • WEAK CYP3A4 INHIBITORS/ELIGLUSTAT
  • STRONG CYP3A4 INHIB;MODERATE 3A4 & P-GP DUAL INHIB/NERATINIB
  • SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/VENETOCLAX
  • SELECTED INHIBITORS OF P-GP OR BCRP/PAZOPANIB
  • WEAK CYP3A4 INHIBITORS/LOMITAPIDE (<=30MG)
  • AGENTS THAT AFFECT IODIDE/RADIOACTIVE IODIDE
  • P-GLYCOPROTEIN (P-GP) INHIBITORS/TOPOTECAN
  • SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/DABIGATRAN
  • VITAMIN K/SELECTED ANTICOAGULANTS (VITAMIN K ANTAGONISTS)
  • Moderate Interactions

    These medications may cause some risk when taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation.

  • MODERATE AND WEAK CYP3A4 INDUCERS/TACROLIMUS
  • FOLIC ACID/PAFOLACIANINE
  • SLT MODERATE AND WEAK CYP3A4 INHIBIT/SIROLIMUS PROTEIN-BOUND
  • POLYVALENT CATIONS/ROXADUSTAT
  • POLYVALENT CATIONS/CABOTEGRAVIR
  • MODERATE AND WEAK CYP3A4 INDUCERS/UBROGEPANT
  • WEAK CYP3A4 INHIBITORS/UBROGEPANT
  • WEAK CYP3A4 INHIBITORS/LEMBOREXANT (<= 5 MG)
  • MODERATE AND WEAK CYP3A4 INHIBITORS/TACROLIMUS
  • SELECTED MINERALS, ORAL/TRIENTINE
  • FAT SOLUBLE VITAMINS/COLESEVELAM
  • POLYVALENT CATIONS/BALOXAVIR
  • SELECT P-GP INHIBITORS/EDOXABAN (<= 30 MG)
  • SEL ORAL CATIONS; ANTACIDS; H2 ANTAG/DOLUTEGRAVIR-RILPIVIRIN
  • SELECTED MODERATE CYP3A4 INHIBITORS/ACALABRUTINIB
  • SELECTED P-GLYCOPROTEIN (P-GP) INHIBITORS/BETRIXABAN
  • SELECT P-GP INHIBITORS/EDOXABAN (> 30 MG)
  • SELECTED MODERATE-WEAK CYP3A4 INDUCERS/EXEMESTANE
  • SELECTED ORAL CATIONS/DOLUTEGRAVIR
  • P-GLYCOPROTEIN (P-GP) INHIBITORS/AFATINIB
  • SELECTED ORAL CATIONS/ELVITEGRAVIR
  • SELECTED ORAL CATIONS/SELECTED ORAL QUINOLONES
  • GLUCOSAMINE AND-OR CHONDROITIN/COUMARIN ANTICOAGULANTS
  • SELECTED ORAL CATIONS/SELECTED ORAL QUINOLONES
  • POLYVALENT CATIONS/ELTROMBOPAG
  • DI-; TRIVALENT CATIONS/CHLOROQUINE; HYDROXYCHLOROQUINE
  • ORAL MULTIVALENT CATIONS/ORAL BISPHOSPHONATES
  • FAT SOLUBLE VITAMINS/ORLISTAT
  • DIVALENT & TRIVALENT CATIONS/TETRACYCLINES
  • Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

    CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.